The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Highlight Therapeutics; ImaginAb; ImmPACT-Bio; Inspirna; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; Pluto Immunotherapeutics; RAPT Therapeutics; Synthekine; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Timothy J. Panella
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Castle Biosciences (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Accutar Biotech (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); OncoC4 (Inst); Oncorus (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Takeda (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Edgardo S. Santos
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Regeneron
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers-Squibb; EMD Serono; G1 Therapeutics; Genentech/Roche; Genzyme; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Pfizer; Regeneron; SOBI; Takeda
 
Jill S. Clancy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Mahgull Nazar Thakur
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Anna Polli
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alessandra Di Pietro
Stock and Other Ownership Interests - Pfizer; Pfizer
Honoraria - Pfizer
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; AstraZeneca; Bayer; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; Pfizer; Replimune